Skip to main content
OpenTrials
Completed

NCT Number: NCT01169675

BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours

This Phase I study will investigate the safety of BIBW 2992 in combination with standard dose pemetrexed (500mg/m2) given on a 21 day cycle in patients with advanced solid cancers. BIBW 2992 will be given on two different dose schedules; dosing on days 1-21 and dosing on days 1 to 6 of a 21 day cycle.

The use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), including BIBW 2992 have demonstrated efficacy in solid tumors including non-small cell lung cancer (NSCLC). In addition, pemetrexed has demonstrated efficacy and has been approved as single agent chemotherapy in second-line NSCLC patients with adenocarcinoma. The data obtained from this trial shall allow for a conclusion as to whether BIBW 2992 may be safely administered in advanced cancer patients in combination therapy with pemetrexed.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

1200.92.1001 Boehringer Ingelheim Investigational Site, Edmonton, Alberta, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 or older.
  • Eastern cooperative oncology group performance status of 0-2.
  • Life expectancy of at least 12 weeks.
  • Measurable disease according to Response evaluation criteria in solid tumors 1.1 criteria.
  • Written informed consent

Exclusion criteria

  • Treatment with an investigational drug within the past 28 days prior to the start of therapy
  • Persisting toxicities which are clinically significant from previous therapy
  • Patients who are unwilling or unable to take folic acid and vitamin B12 supplementation
  • Active brain metastases
  • Other active malignancy diagnosed within the past 3 years
  • Concomitant intercurrent illnesses that would limit compliance with trial requirement
  • Patients unable or unwilling to interrupt concomitant administration of Non-steroidal anti-inflammatory drugs (NSAIDS) as per pemetrexed prescribing information
  • Patients who have received prior therapy with BIBW 2992
  • Left ventricular function by echocardiogram or Multiple gated acquisition scan (MUGA) less than institutional lower limit of normal
  • Absolute neutrophil count (ANC) less than 1,500/mm3
  • Platelet count less than 100,000/mm3
  • Hemoglobin less than 90g/L
  • Total bilirubin less than 26µmol/L
  • Alanine amino transferase (ALT) and/or aspartate amino transferase (AST) greater than 2.5 X ULN, except in case of known liver metastasis where maximum 5 X ULN is acceptable
  • Serum creatinine level greater than 133µmol/L and/or creatinine clearance (measured or calculated) less than 45 ml/min
  • History or recent gastrointestinal bleeding, obstruction or perforation or malabsorption syndrome and must be able to swallow the BIBW 2992 in whole by mouth.
  • History of interstitial lung disease
  • Women and men who are sexually active and unwilling to use a medically acceptable method of contraception
  • Pregnancy or breast feeding
  • Known or suspected active alcohol or drug abuse
  • Patients unable to comply with the protocol
  • Has a diagnosis of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
  • Any known hypersensitivity to the trial drugs or their excipients

Treatment and study plan

BIBW 2992 low dose

Drug

patient receives low dose BIBW 2992 po daily on day 1 of 21 day cycle

BIBW 2992 high dose

Drug

patient receives high dose BIBW 2992 po daily on day 1 of 21 day cycle

Pemetrexed

Drug

given intravenously on day 1 of a 21 day cycle

BIBW 2992 high dose 6 day

Drug

patient receives high dose BIBW 2992 po daily on days 1-6 on 1 of 21 day cycle

BIBW 2992 low dose 6 day

Drug

patient receives low dose BIBW 2992 po daily on days 1-6 on day 1 of 21 day cycle

BIBW 2992 medium dose 6 day

Drug

patient receives medium dose BIBW 2992 po daily on day1 to 6 of a 21 day cycle

BIBW 2992 medium dose

Drug

patient receives medium dose BIBW 2992 po daily on day 1 of 21 day cycle

Primary outcomes

  1. Investigator Defined Dose Limiting Toxicity (DLT) During First Course of Treatment, Treated Set

    Time frame: DLT were assessed during the first cycle (days 1-21)

    Occurence of DLT during the first course of treatment to determine the maximum tolerated dose (MTD) of Afatinib at two different dose schedules in combination with the standard established dose of pemetrexed (500 mg/m2).

Secondary outcomes

  1. Investigator Defined Dose Limiting Toxicity (DLT) During All Courses of Treatment, Treated Set

    Time frame: DLT were assessed during all cycles of treatment

    Occurence of DLT during all courses of treatment with Afatinib at two different dose schedules in combination with the standard established dose of pemetrexed (500 mg/m2).

  2. Objective Response (OR)

    Time frame: Every 6 weeks before week 48 and every 12 weeks after week 48 until progression

    Objective Response is defined as complete response or partial response according to the response evaluation criteria in solid tumours (RECIST) version 1.1.

    Complete Response (CR): disappearance of all non-target lesions and normalization of tumor marker level; Partial Response (PR): at least 30% decrease of the sum of longest diameter (LD) of target lesions; Progressive Disease (PD): at least a 20% increase in the sum of LD of target lesions together with an absolute increase in the sum of LD of at least 5 millimeters; Stable Disease (SD): neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD.

  3. Disease Control

    Time frame: Every 6 weeks before week 48 and every 12 weeks after week 48 until progression

    Disease Control is defined as complete response, partial response, or stable disease according to the response evaluation criteria in solid tumours (RECIST) version 1.1.

  4. Progression Free Survival (PFS)

    Time frame: Every 6 weeks before week 48 and every 12 weeks after week 48 until progression

    PFS was defined as the time from the first treatment to the occurence of tumour progression or death, whichever came first. It was assessed according to RECIST version 1.1 criteria.

  5. Tumour Shrinkage

    Time frame: Every 6 weeks before week 48 and every 12 weeks after week 48 until progression

    Tumour shrinkage is defined as the maximum percentage decrease from baseline in the sum of the longest diameters of target lesions.

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

BIBW 2992 Phase I Combination With Pemetrexed in Advanced Solid Tumours

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
Jul 26, 2010
Registry last updated
Jun 9, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.